Home » Articles » Shanley

From the Editor: Long Live the Revolution!

Evolutionary change is good, but as Takeda’s EVP Tadataka Yamada recently said, revolutionary change is best. Just remember that it is built on the back of failure.

By Agnes Shanley, Editor in Chief

I apologize if some of my columns over the years have seemed a bit negative or critical.

As a publication, we started up at a time when thought leaders pointed out the seemingly limitless potential, and need, to improve and modernize manufacturing.

Since then, we’ve had more than enough reminders of where pharma is falling short: questionable marketing practices, failures to comply with quality standards, to investigate patient reactions, to vet suppliers, embrace new technology or assess potential risk. There’s variability everywhere, from the loading of active ingredient in generic medications to the quality of raw materials, to the way operations are carried out on individual lines and at different facilities.

As we start a new year, though, perhaps it’s a good idea to take stock of the very tangible results that all of you have achieved over the past few years. Over the last eight decades, your efforts have helped move the average life expectancy for the U.S. woman from 62 to 80 years.

Your products save lives. Vaccines alone save more than 2 million lives each year, according to the International Federation of Pharmaceutical Manufacturers and Associates (IFPMA).

In the difficult war against cancer, victories can also be mentioned. Despite failures, such as Merck KGaA’s proposed vaccine, new therapies are having some impact. Cancer death rates in the United States have dropped by 18% since the early 1990s, according to the American Society of Clinical Oncology, and two of three U.S. cancer patients live at least five years after a diagnosis (in the 1970s that figure was 1 of 2). Pharma needs to take a long-term view of its individual failures, as Takeda’s EVP, Tadataka Yamada, reminded senior managers at a recent New York Pharma Forum meeting “Pharma needs a willingness to fail and to fail often because success is built on the back of failure.”

Fortunately, new technologies for plant construction and single-use processing technologies allow companies to move on, faster and with less financial risk than in the past, as this month’s cover story makes clear.

In addition to addressing its fear of failure, Dr. Yamada said, pharma needs to develop better ways to measure success. “It’s easy to measure success by the number of product launches and INDs, he said, “but how about tracking the number of lives saved and the overall advancement of society? As an industry, we’re bad at that; we’re only following surrogate markers.”

He quoted Bill Gates: “Humanity’s greatest advances lie not in its discoveries but in how they are applied to reduce inequity,” arguing that revolutionary innovation, brought about by a sense of urgency and concern for the big picture, will be the key to pharma’s future success, and to transforming its public image.

While building capacity in emerging markets, he said, pharma companies must become partners in addressing these nations’ most pressing problem: The fact that 8 million children under the age of five die each year, unnecessarily, from easily preventable and treatable diseases. He also reminded pharma of ongoing challenges in developed markets, mentioning concerns about drug-resistant strains of tuberculosis. 

It is you who will solve these problems on the ground, and continue to transform drug making into the efficient and reproducible process that it can be.

Here’s hoping that you won’t shy away from change, however difficult, or discourage its agents among you. Patients ultimately depend on you, and there’s just too much evidence that doing things differently pays off, whether that’s trying a Lean or Six Sigma approach, piloting QbD, or implementing a PAT method.

On a small and personal level, I am also writing to say goodbye. It has been an honor to help chronicle all the positive changes that you have been making. Manufacturing cannot be a stepchild in the industry of tomorrow, and this publication will continue to document change, both evolutionary and revolutionary. 

---

More From This Voice:

From the Editor: Long Live the Revolution!
01/15/2013
Evolutionary change is good, but as Takeda’s EVP Tadataka Yamada recently said, revolutionary change is best. Just remember that it is built on the back of failure.

From the Editor: Quality Systems Lessons from NECC
11/29/2012
Is the risk of operating unsafely ever worth the short-term reward?

From the Editor: The Long Arm of Lean
10/10/2012
Lean’s influence is being felt far beyond the plant floor, but there’s still a long way to go.

From the Editor: Protecting the Wind
07/31/2012
What would happen if everyone tried to patent good science, and the way to a good Design Space?

From the Editor: Inspiration and Innovation
06/18/2012
The yin is just as important as the yang; sometimes, even more so.

From the Editor: Brush Up on Statistics (Or Face the Consequences)
05/09/2012
Are you using statistics to support the status quo, or to get to true root cause?

From the Editor: Pangloss or Popper: Has Drug Manufacturing Advanced in the Past Decade?
04/11/2012
Can drug manufacturing reach its potential without standards, science and an admission that there’s a need for improvement?

From the Editor: The Cost of Poor Quality, Too High a Price?
02/29/2012
Assessing the cost of poor quality doesn’t just prevent disasters; it’s good for business.

From the Editor: A Culture of Arrogance
02/03/2012
Analysts say that 2012 may prove to be pharma’s most challenging year ever.

From The Editor: First, Do No Harm
02/01/2012
Modern control is the best way to ensure patient safety (and corporate survival).

From the Editor: Adulteration, 21st Century Style
11/30/2011
As legislators and the courts re-examine an old fashioned word, sins of omission will count as much, if not more, than sins of commission.

From the Editor: Entropy: Can the Center Hold at Your Facility?
10/24/2011
Operations, like natural systems, are drawn to chaos. Only energetic management can stop the slide.

From the Editor: Knowledge Transfer and Minimizing Risk
09/27/2011
When GMP's fail offshore, insufficient knowledge transfer is usually at the root of the problem.

From the Editor: Channeling General Patton
08/02/2011
Pharma could learn a few lessons in accountability and respect.

From the Editor: Drug Prices? Eenie Meenie Miney Mo
06/14/2011
For an industry rooted in science, why are drug prices set so unscientifically?

From the Editor: Is the “Desired State” Really Desired?
05/10/2011
Research suggests that a dysfunctional relationship between regulator and regulated is delaying pharma’s progress.

From the Editor: Why Can’t Pharma Think More Like Chem?
04/05/2011
Using physical material attributes allows for much tighter control of processes and product quality. Could a new excipient database be a model for pharma?

From the Editor: Who Needed PAT and QbD, Anyway?
03/14/2011
Has the industry been on the road to Oz? Didn’t we already have what we needed…in the GMP code and good engineering principles?

From the Editor: Defining the Design Space
02/15/2011
How can you talk your CEO into paying for Quality by Design if you can’t even agree on what its core concepts mean?

From the Editor: Guiding the Invisible Hand
12/30/2010
Drug shortages kill patients every day, right here in the U.S. It’s time for creative, market-based solutions.

From the Editor: GMPs in the Courtroom
12/06/2010
The connection between cGMP’s and fraud is difficult, but possible, to make. Expect more people to try.

From the Editor: Don't Sing the Motown Blues
10/06/2010
Automotive, and pharma, innovation are far from dead, but will we see the type of innovation that survival demands?

From the Editor: Just Where Does the Buck Stop?
09/10/2010
If senior management is held directly accountable for cGMP problems, could we see a very different approach to manufacturing?

From the Editor: How Good is Your Data (And Can You Find It)?
08/02/2010
Forget, for the moment, about process understanding and control. How are you doing on basic document retrieval?

From the Editor: Who Is Your Customer?
06/10/2010
Pharma has many customers today. But is it focusing on the ones that will help it improve quality and drive innovation?

From the Editor: Can Healthcare Reform Cure a Risk-Averse Pharma?
05/06/2010
Pressures to boost output, with lower short-term profits, will drive name-brand and generic companies alike to new technologies, and tools such as PAT. Or will they?

From the Editor: Accountability & the Employee Empowerment Myth
04/07/2010
Individuals cannot perform well if there are basic problems with the systems in which they operate

From the Editor: Are You Myopic About Risk?
03/08/2010
Two years after the heparin disaster, the drug industry is still vulnerable to major quality, safety and security risks.

From the Editor: Ordinary Measures
02/02/2010
Everything I needed to know I learned in Freshman Chemistry 101

From the Editor: Stop Throwing Processes Over the Wall
01/06/2010
Pharma tech transfer may be complex, yet it is often held up by simple problems such as failure to plan or share information

From the Editor: Lurching Toward Agility
12/03/2009
Agility won’t come overnight, but we’re already catching glimpses of the pharmaceutical facility of the future

From the Editor: Gobsmacked
10/09/2009
Market forces already demand a smarter management style, better technology and a science-based quality toolkit, for both name-brand and generics

From the Editor: Process Knowledge = Patient Safety: Lessons from Mylan Morgantown
09/03/2009
How can jidoka, process control and PAT work if a facility’s or company’s culture does not promote the right values?

From the Editor: Share the Risk, If You Dare
07/22/2009
Can the act of quantifying and promising results for customers, and taking a hit if they’re not met, actually improve one’s own performance?

From the Editor: H1N1, Shamanism and Shame
06/18/2009
Thirty-three years after the last “Swine flu” scare, we still cannot seem to make flu vaccine and antiviral manufacturing any more predictable. Are today’s solutions like amulets whose power cannot last?

From the Editor: Excipients: Out of Sight, Not Out of Mind
05/13/2009
Questions of QbD, supply chain management, anticounterfeiting and adverse reactions cannot end with the formulation or active ingredient. PAT will be essential

From the Editor: When Voluntary Becomes Mandatory
04/07/2009
As the period of introspection within FDA comes to an end, so does the time for playing “wait and see” with PAT, statistical process control, process capability and risk triage

From the Editor: Visiting Toyota
03/05/2009
The automaker is now entering a mature, more challenging phase of its history, yet has managed to keep its core principles intact. are there lessons here for pharma?

Visiting Toyota
02/26/2009
The automaker is now entering a mature, more challenging phase of its history, yet has managed to keep its core principles intact. Are there lessons here for pharma?

From the Editor: Get Off the Bench and Into the Game
01/19/2009
Support from senior executives will advance your career—but you’ll have to reinterpret the language of cost accounting for them, using real-time value and KPis.

From the Editor: Validating Process Validation
12/10/2008
FDA’s new draft guidance gets to the essence of what process validation is, and isn’t. Have you read it yet?

From the Editor: Deconstructing Murphy
10/23/2008
The person who can smile when things go wrong has thought of someone else he can blame it on. --Robert Albert Bloch*

From the Editor: e-Pedigrees: A Little Less Conversation (and a Little More Action, Please)
09/23/2008
All this inactivity can’t be a good thing.

From the Editor: Better Science = Better Business
08/18/2008
Revamping pharmaceutical education is key to improving drug development and manufacturing.

From the Editor: Mistake Proofing Pharma
06/23/2008
How can pharma reach the “Desired State” when so many of its workplaces still encourage technicians and operators to make mistakes?

From the Editor: The Right Stuff
05/15/2008
As it develops its quality systems and risk management strategies, pharma can learn a lot from military aviation

From the Editor: QbD and the People Space
04/09/2008
In addition to the Design Space and the Control Space, should the “People Space” be added to the QbD lexicon?

From the Editor: Curing Pharma’s China Syndrome
02/28/2008
Accountability - on the part of finished drug manufacturers as well as their API suppliers - will prevent future quality and P.R. disasters

From the Editor: There’s Room for All at the Table — Isn’t There?
02/15/2008
Should any single group have a monopoly on science-based standards?

From the Editor: Rx for the New Year: Optimism and Enlightened Self-Interest
01/15/2008
You’re already applying operational excellence at work. Are you applying it to your own career planning and development?

From the Editor: Confused About Quality?
11/27/2007
Is the industry equipped for full-fledged QbD?

From the Editor: Rx for the Industry: Manufacturing Research
10/05/2007
More concerted research efforts are needed to advance drug manufacturing, wherever it takes place.

From the Editor: Information Access Is the Key to High-Tech Pharma
09/17/2007
Concrete steps are being taken to help drug manufacturing reach the level of technical sophistication that other manufacturing fields take for granted.

From the Editor: Can Your Data Stand Up in Court?
07/27/2007
Rumors of 21 CFR Part 11’s demise have been greatlly exaggerated. Data integrity is at the heart of numerous 483s and a recent lawsuit against Novartis.

From the Editor: Let’s Ditch Dilbert
06/12/2007
The devaluation of science and engineering in the U.S. is both a cause and an effect of increased offshoring. Can and will this problem be addressed?

From the Editor: Pharma and the Power of Web 2.0
04/18/2007
Individuals within the pharmaceutical industry are empowered, as never before, to make changes for the better.

From the Editor: Get to Know Shingo
03/23/2007
The “other” Toyota engineer focused on the little things, the details, that collectively waste $50 billion in the drug industry each year.

From the Editor: Deconstructing the Blockbuster Model
02/28/2007
The cherished blockbuster is at the root of many of the industry’s problems today. Solving them will depend on an energized industry and an adequately funded FDA.

Protecting Our Human Capital
02/05/2007
Projected increases in M&A activity demand careful risk vs. benefit analysis, and not only on the ledger sheet

From the Editor: Into the Light
12/08/2006
Drug manufacturing can only advance if drugmakers, regulators, academics and vendors join forces to mine and interpret new data.

From the Editor: The Value of Lean, or Lean Values
10/09/2006
When will pharma's Lean index catch up with its "Mean" index?

From the Editor: Only Connect!
09/20/2006
Quality by Design cuts across job functions and requires a vision of the “big picture.” This requires connecting data, concepts and people. Is your organization doing this?

From the Editor: Isn’t It Time to Update cGMPs?
08/03/2006
FDA needs to improve its public communications and to connect older written guidances, such as cGMPs, to its new initiatives.

From the Editor: Japan Globalizes, But Won’t Compromise on Core Values
06/08/2006
Japan has embraced ICH, but doesn’t yet have any official “mutual recognition” policy with FDA regarding GMP inspections. The nation also maintains a unique position on clinical trials, which influences many drug manufacturing decisions. Can genomics resolve a highly politicized issue? MIT scholar Dr. Wen-Hua Kuo shares his insights.

From the Editor: Lessons from Shingo
05/04/2006
Our survey on pharmaceutical operational excellence suggests that many drug companies still fail to take seriously two fundamental principles of manufacturing.

Will USP and FDA Reach Consensus on Stability Testing?
04/04/2006
Standards will guide drug manufacturing's future, if everyone can agree on what's important.

Think Outside the “Technology” Box
02/27/2006
Technology, no matter how powerful, can only work as part of an overall strategy of control and continuous improvement.

PhRMA and ‘the Smartest Guys in the Room’
01/31/2006
Be sure your communications match the image you’d like others to have of you.

Building Community in an Age of Anxiety
01/18/2006
At a time when no job is truly secure, knowledge and a global outlook are essential.

From the Editor: The DRIP (Data Rich, Information Poor) Syndrome
12/01/2005
Despite significant investments in information technology, knowledge-based pharma remains “knowledge poor” in its day-to-day operations at every step of the value chain, from discovery through distribution.

Retooling the U.S. Workforce: Sputnik or Jihad?
10/06/2005
Post-9/11 immigration policies threaten U.S. innovation.

From the Editor: Control = Survival
08/30/2005
Pharmaceutical process control is advancing, but will its progress be fast enough?

Right First Time Works for Public Relations, Too
08/03/2005
It’s time for the drug industry’s face to become something other than that of the “pharma sales rep.”

From the Editor: A New World Order
07/27/2005
Fundamental innovations in manufacturing will determine who survives.

On the Trail of the Celtic Tiger
07/22/2005
Ireland’s pharmaceutical base faces stiff competition from lower cost centers, but it’s clearly on the leading edge.

From the Editor: Think Like An Engineer
06/09/2005
Chemists, pharmacists and biologists need to bridge the divide.

From the Editor: Best Practices or Trade Secrets?
05/04/2005
Security must be a top priority for drug makers, but overly restrictive noncompete and nondisclosure agreements and publishing practices verge on the paranoid – and prevent the exchange of “best practices” that the industry needs in order to improve.

From the Editor: We Need Real Data on Counterfeits and Real Debate on Imports
04/14/2005
Until data gathering is taken seriously, the extent of the counterfeiting problem will never be known.

From the Editor: Blasting Down the Barriers
04/07/2005
Teams may be a new concept for pharma, but they’re already transforming its “silo” culture. 2005 Team of the Year finalists offer a glimpse into the future of pharmaceutical manufacturing.

From the Editor: Striking a Balance
02/02/2005
Legitimate concerns over patent protection, profits and shareholder value are being balanced by ethics and humanism

PAT Means Revolution — For FDA, Too
11/24/2004
PAT demands cultural change, not only within pharmaceutical manufacturing companies but also within FDA. Currently, the skills, training and background of FDA inspectors vary widely. Can they make the leap from the traditional chemistry-based quality approach to a future grounded in analytics and instrumentation?

From the Editor: The Quest for Excellence
09/14/2004
The pharmaceutical industry needs clarity on Six Sigma and Quality concepts. It also needs its own version of the Baldrige award, recognizing the manufacturing effort and commitment to continuous quality improvement.

The Fear Factor vs. Open Communications
04/01/2004
The "don't ask, don't tell" mentality is still alive and well, a pharmaceutical manufacturing whistleblower suggests.